Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NVX-CoV2705 · 1 trial · 2 indications
Pseudovirus neutralization (ID50) GMFR for the Omicron JN.1 subvariant at Day 28 following study vaccination.
| Arm | Type | Description |
|---|---|---|
| NVX-CoV2705 | EXPERIMENTAL | NVX-CoV2705 vaccine in a 0.5 mL injection volume at an antigenic dose of 5 µg with 50 µg Matrix-M adjuvant. |
| Name | Type | Description |
|---|---|---|
| NVX-CoV2705 | BIOLOGICAL | Intramuscular (deltoid) injection at an antigenic dose of 5 µg with 50 µg Matrix-M adjuvant. |
Inclusion Criteria: * To be included in this study, each individual must satisfy all the following criteria: 1. Participants ≥ 65 years of age and participants 12 through 64 years who have at least one underlying condition that puts them at high risk of severe outcomes from COVID-19 at time of s...
NVX-CoV2705 is an investigational monoclonal antibody being developed for COVID-19, specifically for the prevention or treatment of SARS-CoV-2 infection. It is currently in Phase 3 clinical development and has not been approved by regulatory authorities.
NVX-CoV2705 is being developed by Sanofi, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol SNY. The company is conducting clinical trials to evaluate the safety and immunogenicity of this investigational monoclonal antibody for COVID-19.
NVX-CoV2705 is in Phase 3 clinical development. It is an investigational drug and has not yet been approved by regulatory agencies. The Phase 3 trial has been completed, and the drug remains under evaluation for its safety and immunogenicity in the context of COVID-19.
NVX-CoV2705 has been studied in one completed Phase 3 clinical trial with the identifier NCT07079670. This trial, titled 'Safety and Immunogenicity of NVX-CoV2705,' enrolled 676 participants in the United States, including healthy volunteers aged 12 years and older, to assess the drug's safety and immune response.
Yes, NVX-CoV2705 is a monoclonal antibody, a type of biologic drug designed to target specific proteins. It is being investigated for its potential role in addressing COVID-19 and SARS-CoV-2 infection, though it remains in clinical development and is not yet approved.